Compare Eli Lilly And Co (LLY) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Rigetti Computing Inc — how do they compare? Eli Lilly And Co trades at $1,177 (market cap $1.04T), while Rigetti Computing Inc trades at $14.04 (market cap $4.72B). The key difference: Eli Lilly And Co is far larger — about 220.3× Rigetti Computing Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Rigetti Computing Inc for 35 Days on average.
| LLY | RGTI | |
|---|---|---|
Market Cap | $1.04T | $4.72B |
Volume | 3,064,878 | 17,136,381 |
Sector | Health | Technology |
52-Week High | $1.28K | $56.34 |
52-Week Low | $799.57 | $12.90 |
Typical Hold Time | 93 Days | 35 Days |
Enterprise Value | $1.09T | $4.33B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
RGTI trades at $14.04, down 3.77% today, with a bearish technical signal despite bullish oscillators. The company shows minimal revenue of $7.09M in 2025 with a massive net loss of -$216.21M, resulting in negative profit margins. Analyst consensus is strongly bullish with 6 buy ratings and a $21.67 price target, representing 54% upside. Recent news highlights quantum computing sector momentum and Rigetti's hybrid quantum-HPC strategy with partners like HPE.
While analyst optimism and quantum computing potential offer significant upside, RGTI faces substantial execution risks with negative cash flow, high valuation multiples, and intense competition. The stock presents high-risk/high-reward potential for investors willing to tolerate volatility in exchange for quantum computing exposure, but requires careful monitoring of commercialization progress and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
